SWOG clinical trial number
CTSU/E2204

An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination with Gemcitabine and in Combination with Chemoradiation (Capecitabine and Radiation) in Patients with Completely-Resected Pancreatic Carcinoma

Closed
Phase
Abbreviated Title
PANCREAS
Activated
10/15/2006
Closed
01/09/2008
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Gemcitabine hydrochloride Radiation Therapy Bevacizumab Capecitabine Cetuximab

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group participated in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information.

Publication Information Expand/Collapse

2018

An intergroup randomized phase II study of bevacizumab or cetuximab in combination with gemcitabine and in combination with chemoradiation (capecitabine and radiation) in patients with resected pancreatic carcinoma: a trial of the ECOG-ACRIN Cancer Research Group (E2204)

JD Berlin;Y Feng;P Feng;P Catalano;J Abbruzzese;P Philip;RR Mcwilliams;A Lowy;A Benson;W Blackstock Oncology 94(1):39-46

PMid: PMID29040974 | PMC number: PMC5828967

2010

ECOG 2204: An intergroup phase II study of cetuxamab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC)

J Berlin;PJ Catalano;Y Feng;AM Lowy;AW Blackstock;PA Philip;RR McWilliams;J Abbruzzese;AB Benson Journal of Clinical Oncology 28:7s (suppl; abstr 4024) poster

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
71%
Open
Phase
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
27%
Open
Phase